Tempus AI (NASDAQ:TEM) Shares Cross Above 50 Day Moving Average – Here’s Why

Tempus AI, Inc. (NASDAQ:TEM)’s share price crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $69.70 and traded as high as $72.89. Tempus AI shares last traded at $72.15, with a volume of 5,070,135 shares changing hands.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Large Bristol Myers Squibb and Pathos agreement: Tempus disclosed agreements expected to provide approximately $192.5 million in aggregate cash payments over about five years. The oncology portion gives Bristol Myers Squibb access to Tempus’ multimodal oncology data, Lens software and related analytical services through 2031, strengthening the company’s recurring data and applications revenue outlook. Tempus AI Gains After New Bristol Myers Deal and EU Diagnostic Certification
• Positive Sentiment: European regulatory milestone: Tempus’ xR RNA-sequencing assay received EU IVDR Class C certification for solid-tumor genomic profiling. The certification may support broader adoption of the diagnostic in Europe and enhance the credibility of Tempus’ clinical testing business. Tempus Receives IVDR Certification for xR RNA Sequencing
• Positive Sentiment: Analyst support and earnings expectations: BTIG reaffirmed its buy rating and an $80 price target. Analysts are also expecting Tempus to potentially exceed consensus estimates in the upcoming report, which could provide another catalyst if revenue growth and cash management meet expectations. Tempus AI Expected to Beat Earnings Estimates
• Neutral Sentiment: Personalis acquisition remains an important uncertainty: Tempus has a pending approximately $1.5 billion deal for Personalis. Investors may look to the earnings report for updates on closing, financing and the strategic benefits of the transaction. The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
• Negative Sentiment: Profitability and dilution concerns persist: Tempus remains unprofitable, and continued cash burn could pressure the valuation or require additional financing. In addition, reported insider activity over the past six months consisted entirely of sales, including substantial selling by senior executives, which may weigh on investor sentiment. What Happens To Tempus AI Stock If Its Cash Burn Continues?

Analysts Set New Price Targets

A number of research firms have commented on TEM. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a report on Friday, October 23rd. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Raymond James Financial set a $80.00 target price on shares of Tempus AI in a research note on Wednesday, September 2nd. Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. Finally, HC Wainwright lifted their target price on shares of Tempus AI from $66.00 to $68.00 and gave the stock a “buy” rating in a report on Monday. Eleven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $72.47.

Tempus AI Stock Up 7.4%

The company has a market cap of $13.02 billion, a P/E ratio of -50.10 and a beta of 3.54. The stock has a 50 day moving average price of $69.70 and a two-hundred day moving average price of $56.95.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.22) earnings per share. Equities analysts anticipate that Tempus AI, Inc. will post -1.43 EPS for the current year.

Insider Buying and Selling

In other Tempus AI news, CEO Eric P. Lefkofsky sold 250,000 shares of Tempus AI stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $77.47, for a total value of $19,367,500.00. Following the completion of the sale, the chief executive officer owned 100,000 shares in the company, valued at $7,747,000. The trade was a 71.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan M. Bartolucci sold 7,062 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $75.00, for a total transaction of $529,650.00. Following the completion of the sale, the chief accounting officer directly owned 60,804 shares of the company’s stock, valued at $4,560,300. This represents a 10.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,030,965 shares of company stock valued at $69,882,564 in the last 90 days. 24.26% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after purchasing an additional 821,490 shares during the period. Amova Asset Management Americas Inc. boosted its stake in shares of Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after buying an additional 821,490 shares during the period. Eagle Health Investments LP bought a new stake in shares of Tempus AI in the first quarter valued at approximately $11,588,000. Swiss National Bank boosted its stake in shares of Tempus AI by 0.3% in the first quarter. Swiss National Bank now owns 183,500 shares of the company’s stock valued at $8,298,000 after buying an additional 600 shares during the period. Finally, Aristotle Atlantic Partners LLC acquired a new stake in Tempus AI during the first quarter worth approximately $6,179,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.